Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-Q
2023 Q1
Quarterly report
2 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
2 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
8 Jan 24
8-K
Regulation FD Disclosure
22 Jun 23
8-K
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
22 Jun 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
8-K
Entry into a Material Definitive Agreement
3 Mar 23
8-K
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
9 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
13 Dec 22
8-K
Departure of Directors or Certain Officers
2 Nov 22
8-K
Entry into a Material Definitive Agreement
19 Sep 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
Registration and prospectus
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Mar 24
S-8
Registration of securities for employees
2 Aug 23
S-8
Registration of securities for employees
2 Aug 22
S-3ASR
Automatic shelf registration
2 Mar 22
424B5
Prospectus supplement for primary offering
15 Oct 21
424B5
Prospectus supplement for primary offering
12 Oct 21
S-8
Registration of securities for employees
5 Aug 20
Proxies
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
20 Apr 21
DEF 14A
Definitive proxy
20 Apr 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEF 14A
Definitive proxy
21 Apr 20
PRE 14A
Preliminary proxy
8 Apr 20
Other
UPLOAD
Letter from SEC
16 Apr 20
CORRESP
Correspondence with SEC
15 Apr 20
UPLOAD
Letter from SEC
13 Apr 20
CT ORDER
Confidential treatment order
9 Nov 18
CT ORDER
Confidential treatment order
12 Sep 17
CT ORDER
Confidential treatment order
19 Jan 17
CT ORDER
Confidential treatment order
4 Oct 16
EFFECT
Notice of effectiveness
5 May 15
CORRESP
Correspondence with SEC
4 May 15
UPLOAD
Letter from SEC
29 Apr 15
Ownership
4
Hans Lennart Rudolf Wigzell
11 Mar 24
4
Bilal Arif
11 Mar 24
4
Louise Rodino-Klapac
11 Mar 24
4
Kathryn Jean Boor
11 Mar 24
4
Ryan Edward Brown
11 Mar 24
4
Ian Michael Estepan
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Ian Michael Estepan
6 Mar 24
4
Stephen Mayo
6 Mar 24